http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
PureTech to Present at Three Upcoming Investor Conferences
-
PureTech to Present at 29th Annual Credit Suisse Virtual Healthcare Conference
-
PureTech Announces Public Filing of Registration Statement on Form 20-F for Planned U.S. Listing on Nasdaq Global Market
-
PureTech Appoints Kiran Mazumdar-Shaw, Founder and Chairperson of a Leading Global Biopharmaceutical Company, to Board of Directors
-
PureTech to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
-
PureTech Presents New Data Reinforcing Galectin-9 as a Compelling Therapeutic Target and Biomarker for a Range of Cancers at the American Association for Cancer Research Annual Meeting
-
Gelesis Receives Approval to Market PLENITY™ in Europe as a Weight Loss Treatment
-
PureTech Advances LYT-100 (Deupirfenidone) for Treatment of Serious Respiratory Complications that Persist Following Resolution of COVID-19 Infection
-
PureTech to Present at Jefferies Virtual Healthcare Conference
-
PureTech to Present at 19th Annual Virtual Needham Healthcare Conference
-
Gelesis Named One of the World’s Most Innovative Companies for 2020 by Fast Company
-
PureTech Announces First Participant Dosed in Clinical Trial of Wholly-Owned Lymphedema Candidate LYT-100
-
PureTech to Present at 9th Annual SVB Leerink Global Healthcare Conference
-
Gelesis Announces Partnership with Ro on Commercial Launch of Plenity™
-
Gelesis Secures Over $84 Million in New Capital to Support Commercialization of PLENITY™
-
Vedanta Biosciences Awarded $5.8 Million CARB-X Grant to Accelerate Development of VE707 for Multi-Drug Resistant Infections
-
PureTech to Present at Jefferies 2019 London Healthcare Conference
-
PureTech Announces Presentation of New Data Supporting Wholly Owned Immuno-Oncology Programs LYT-200 (anti-galectin-9) and LYT-210 (anti-delta-1)
-
Pivotal Data Presented at ObesityWeek 2019 Highlight the Therapeutic Benefits of PlenityTM in Adults with Obesity and Underscore its Safety and Efficacy in Lower-BMI Overweight Adults
-
New Plenity™ Pivotal Safety and Efficacy Data to be Presented at ObesityWeek 2019
-
PureTech Announces Board Change
-
PureTech Acquires New Clinical-Stage Program LYT-100 to Treat Lymphedema
-
PureTech Announces Issuance of U.S. Patent Covering Compositions of Matter for Immuno-Oncology Program Targeting Galectin-9
-
PureTech Establishes New Corporate Headquarters in Boston’s Seaport District to Support Expansion and Acceleration of Internal R&D Pipeline
-
PureTech Health to Present at Jefferies 2019 Healthcare Conference
-
Promising Clinical Data from Pilot Study of Gelesis’ Novel Hydrogel GS500 Prototype for the Potential Treatment of Chronic Constipation Presented at Digestive Disease Week by Researchers from Massac
-
PureTech Health Affiliates Gelesis and Vedanta Biosciences Announce Presentations at Digestive Disease Week
-
Gelesis Awarded $10.6 (€9.4) Million Grant to Support Commercial Manufacturing of PLENITY™
-
PureTech Health Announces Collaboration with Boehringer Ingelheim to Advance Immuno-oncology Product Candidates using its Lymphatic Targeting Platform
-
Gelesis Granted FDA Clearance to Market PLENITY™ — a New Prescription Aid in Weight Management
-
Gelesis Presents Preclinical Data Showing Proprietary Hydrogel Prevents Harmful Effects of a High-Fat Diet
-
PureTech Health Announces Presentation of Internal Immuno-Oncology Programs at American Association for Cancer Research (AACR) Annual Meeting
-
Gelesis Presents Expanded Data Showing Impact of Gelesis100 Hydrogel on Patients with Prediabetes, Untreated Diabetes, and Elevated Insulin Resistance
-
Gelesis Presents Preclinical Data Showing Proprietary Hydrogel Restores Gut Barrier Function
-
Gelesis Announces Three Presentations at Annual Endocrine Society Meeting
-
PureTech Health to Present at Two Upcoming Investor Conferences
-
Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers
-
Pivotal Weight Loss Data for Gelesis100 Published in Obesity, Including Predictors of Response
-
PureTech Health to Present at Jefferies 2018 London Healthcare Conference
-
Gelesis Announces Presentations of Expanded Pivotal Data at ObesityWeek 2018
-
PureTech Health Collaborator Publishes in Nature Neuroscience Highlighting Key Role of Brain Lymphatics in Neuroinflammatory Conditions Like Multiple Sclerosis
-
PureTech Health Collaborator Publishes in Journal Nature Regarding New Insights into Key Role of Brain Lymphatics in Alzheimer’s and Other Neurodegenerative Diseases
-
PureTech Health Announces Collaboration with Roche to Advance Technology for Oral Administration of Antisense Oligonucleotides
-
Harry Leider, Former Chief Medical Officer of Walgreens, Joins Gelesis as Chief Medical Officer, and Paul Fonteyne, Chairman and Former CEO of Boehringer Ingelheim USA, Joins the Gelesis Board of Dire
-
PureTech Health to Present at Jefferies 2018 Global Healthcare Conference
-
PureTech Health Appoints Joep Muijrers as Chief Financial Officer
-
Gelesis Raises $30 Million to Prepare for Potential Launch of Lead Product
-
Camtek Ltd. (Nasdaq: CAMT) to Ring The Nasdaq Stock Market Closing Bell
-
PureTech Health to Present at Piper Jaffray 2017 Healthcare Conference
-
PureTech Health to Present at Jefferies 2017 Healthcare Conference in London

